Forkhead box protein p3 (Foxp3) is crucial to the development and suppressor function of regulatory T cells (Tregs) that have a significant role in
tumor-associated immune suppression. Development of small molecule inhibitors of Foxp3 function is therefore considered a promising strategy to enhance anti-
tumor immunity. In this study, we developed a novel cell-based assay system in which the NF-κB
luciferase reporter signal is suppressed by the co-expressed Foxp3
protein. Using this system, we screened our chemical library consisting of approximately 2,100 compounds and discovered that a
cancer chemotherapeutic drug
epirubicin restored the Foxp3-inhibited NF-κB activity in a concentration-dependent manner without influencing cell viability. Using immunoprecipitation assay in a Treg-like cell line Karpas-299, we found that
epirubicin inhibited the interaction between Foxp3 and p65. In addition,
epirubicin inhibited the suppressor function of murine Tregs and thereby improved effector T cell stimulation in vitro. Administration of low dose
epirubicin into
tumor-bearing mice modulated the function of immune cells at the
tumor site and promoted their IFN-γ production without direct cytotoxicity. In summary, we identified the novel action of
epirubicin as a Foxp3 inhibitor using a newly established
luciferase-based cellular screen. Our work also demonstrated our screen system is useful in accelerating discovery of Foxp3 inhibitors.